Product: 20-O-Acetylingenol-4-angelate
TRANCE/TNFSF11/RANK L Antibody Summary
| Immunogen |
Antibody was raised against a 14 amino acid synthetic peptide from near the center of human sRANK-L. The immunogen is located within amino acids 140 – 190 of sRANK Ligand.
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
TNFSF11
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
||
| Application Notes |
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
|
||
| Theoretical MW |
35 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
||
| Control Peptide |
|
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
PBS
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
1 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for TRANCE/TNFSF11/RANK L Antibody
- CD254 antigen
- CD254
- ODF
- OPGL
- OPGLOPTB2
- Osteoclast differentiation factor
- Osteoprotegerin ligand
- RANK L
- RANKL
- RANKLreceptor activator of nuclear factor kappa B ligand
- Receptor activator of nuclear factor kappa-B ligand
- sOdf
- TNF-related activation-induced cytokine
- TNFSF11
- TRANCE
- TRANCEODFhRANKL2
- tumor necrosis factor (ligand) superfamily, member 11
- tumor necrosis factor ligand superfamily member 11
Background
The receptor activator of NF-kappaB ligand (RANK-L) is a recently discovered member of the TNF-ligand family involved in the regulation of the T cell-dependent immune response, lymph node organogenesis and bone formation. RANK-L exists as both a normal, transmembrane form and a truncated, soluble form (sRANK-L), both of which can stimulate the receptor. Activation of T cells, such as by treatment with interleukin-7, induces RANK-L production and leads to an increase of osteoclast formation and bone loss. Finally, sRANK-L can activate the antiapoptotic kinase Akt through a signaling complex involving Src kinase and TRAF6, suggesting sRANK-L may also play a role in regulating apoptosis. This antibody will recognize both the soluble form and the uncleaved transmembrane form of RANK-L.